Frederick James de la Vega, M.D. CURRENT PRACTICE 06/2003-present Coastal Neurological Medical Group, Inc. 9850 Genesee Avenue Suite 740 La Jolla, CA 92037 Services: Parkinson s disease, Movement Disorders, botulinum toxin injection, Deep Brain Stimulation (DBS), electromyography/nerve conduction velocity (EMG/NCV), electroencephalography (EEG), migraines, neurodegenerative diseases, dementias and epilepsy Certified Rater: UPDRS, AIMS, UPDysRS, Blepharospasm Scale, NIHSS ACTIVE PRIVILEDGES 06/2003-present Scripps Memorial Hospital, La Jolla 10/2007-present Director: Stroke Program, Scripps Memorial Hospital, La Jolla 01/2008-present Chairman: Section of Neurology, Scripps Memorial Hospital, La Jolla LICENSURE California A81923 Arizona 27837 FELLOWSHIP 07/2002-06/2003 Muhammad Ali Parkinson Research Center: Movement Disorders Barrow Neurological Institute/ St. Joseph Hospital 500 West Thomas Road, Suite 720 Phoenix, AZ 85013 RESIDENCY 06/1999-06/2002 Mayo Graduate School of Medicine: Neurology Department of Neurology 200 First Street S.W. Rochester, MN 55905 INTERNSHIP 1
07/1998-06/1998 Creighton University School of Medicine Creighton University Medical Center/ St. Joseph Hospital 601 North 30 th Street Omaha, NE 68131 MEDICAL SCHOOL 08/2004-05/1998 Creighton University School of Medicine 2500 California Plaza Omaha, NE 68178 Degree: Doctor of Medicine Date Conferred: May 16, 1998 Honors: Cum laude, AOA Organizations: Creighton Medical School Government (Vice President) UNDERGRADUATE 09/1989-03/1994 Harvard University Cambridge, MA 02137 Degree: Bachelor of Arts Date Conferred: March 22, 1994 Honors: Dean s List Organizations: Harvard Lampoon (Editor) 09/1992-12/1992 School for Field Studies Northeastern University 360 Huntington Avenue Boston, MA 02/1993-05/1993 Scripps Institution of Oceanography University of California, San Diego La Jolla, CA 92037 HIGH SCHOOL RESEARCH 09/1986-06/1989 La Jolla High School La Jolla, CA 92037 F. de la Vega, T. Phan, R. McClelland, E. Wijdicks: Long-term outcome of basilar artery occlusion confirmed by magnetic resonance angiography. Poster, American Academy of Neurology 53 rd Annual Meeting, May 9, 2001. Shill H, de la Vega F, Samantha J, Stacy M: Motor Learning in EssentialTremor. Movement Disorders 2009 April 30: 24(6): 926-8 MEMBERSHIP 2
1995-present American Medical Association 1998-present Alpha Omega Alpha 2000-present American Academy of Neurology 2002-present Movement Disorder Society 2002-present American Association of Neuromuscular and Electrodiagnostic Medicine 2003-present San Diego County Medical Society 2003-present San Diego Neurology Society 2003-present San Diego Parkinson s Disease Association 2004-present Neurocritical Care Society GRAND ROUNDS Scripps Memorial Hospital, La Jolla 01/2005 Stroke Program 04/2006 Brain Death Evaluation 05/2008 Stroke Update 05/2009 Stroke Update LECTURES 04/2004 San Diego Ataxia Association Lecture 05/2006 Public Stroke Lecture, La Jolla High School 2006-present Parkinson s disease lectures, Scripps-Mende Well Being Center 01/2008 3
Public Stroke Lecture, La Jolla High School 02/2008 Am I Crazy or is it the Drugs: Non-motor Symptoms of Parkinson s Disease San Diego Parkinson s Disease Association Symposium 08/2009 Parkinson s disease lecture, Scripps Memorial Hospital, La Jolla CLINICAL TRIALS 2004-2007 Berlex BEYOND Phase III Trial: in patients with Multiple Sclerosis. Blinded rater for EDSS and MSFC scales 2004-2008 Novartis STRIDE Phase IV Trial: in patients with Parkinson s disease. Blinded rater for UPDRS scales 2005-2008 Kyowa KW6002 Phase III Trial (025): in patients with Parkinson s disease. Sub- 2005-2008 Novartis QUEST Phase IV Trial: in patients with Parkinson s disease. Blinded rater for UPDRS scales 2005-2008 Novartis FIRSTSTEP Phase IV Trial: in patients with Parkinson s disease. Sub- 2006-2008 Eisai PACE Phase III Trial: in patients with Parkinson s disease. Sub-, 2006-2008 Bayer BEYOND-FU Phase III Trial: in patients with Multiple Sclerosis. Blinded rater for EDSS and MSFC scales 2006-2007 Teva LEGATO Phase IV Trial: in patients with Parkinson s disease. Sub- Eisai PACE-FU Phase III Trial: in patients with Parkinson s disease. Sub- Vernalis APO-01 Phase IV Trial: in patients with Parkinson s disease. Sub- 2007-2009 Novartis OPTIMA Phase IV Trial: in patients with Dementia Alzheimer s Type. Sub- 2007-2009 BIPI PROUD Phase III Trial: in patients with Parkinson s disease. Sub- 2007-2009 Santhera FJORD Phase III Trial: in patients with Parkinson s disease having disabling dyskinesias. AIMS/UDysRS rater 4
Boehringer Ingelheim Pramipexole ER Phase III Trial (524): in patients with newly diagnosed Parkinson s disease. Blinded rater for UPDRS scales 2007-2010 Boehringer Ingelheim Pramipexole ER Phase III Trial (633): in patients with newly diagnosed Parkinson s disease. Sub- Schering-Plough P04501 Phase II Trial: in patients with Parkinson s disease experiencing motor complications. Sub- 2007-2010 Schering-Plough P05175 Phase II Trial: in patients with Parkinson s disease experiencing motor complications. Sub- 2007-2011 Schwarz SP921 Phase III Trial: in patients with advanced Parkinson s disease. Sub- 2008-2009 Teva SONG Phase IV Trial: in patients with Multiple Sclerosis. Sub- 2009-2011 Impax APEX-PD Phase III Trial: in patients with Parkinson s disease. Sub- 2009-2011 Impax ADVANCE-PD Phase III Trial: in patients with advanced Parkinson s disease, Sub- 2009-present Teva ANDANTE Phase IV Trial: in patients with early Parkinson s disease, Sub- 2010-present Impax Open Label Extension Phase III: in patients who completed previous IPX066 trials, Sub- 2010-present Phytopharm CONFIDENT-PD Phase II Trial: in patients newly diagnosed with Parkinson s disease, Sub- 2011-present Acadia Pimavanserin Phase III Trial: in patients with Parkinson s disease psychosis, Sub- 2011-present BiotieSynosia SYN115 Phase IIb Trial: in patients with Parkinson s disease experiencing end of dose wearing off, Sub- 2011-present Addex Gelucire Phase II Trial: in patients with Parkinson s disease experiencing levodopa enduced dyskinesias, Sub- Training/Certifications 5
2004 MSFC and EDSS Assessment Certification, Berlex Pharmaceuticals 2004 UPDRS Training and Certification, Novartis Pharmaceuticals 05/2005 American Stroke Association, NIHSC Certification 2007 Dr. Goetz, UPDRS Qualification, Solvay Pharmaceuticals 2007 AIMS/UDysRS Training and Certification,Santhera Pharmaceuticals 2007 MATTIS DRS-2 Certification, Novartis Pharmaceuticals 01/2008 Collaborative IRB Training Initiative (CITI) Program, Protection of Human Research Subjects 04/2009 Good Clinical Practice, E-learning Training, Novartis Pharmaceuticals 05/2010 Neurostatus and EDSS Assessments, Neurostatus E-Test 12/2010 Phytopharm Pharmaceuticals, Dr. Goetz, UPDRS Qualification Revised: 06/2011 6